Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21769266 | 0.76 | TLR7 (0.41) | TAS1R3TAS1R1P2RX3P2RX2CYP2D6 | |
| SCHEMBL15469980 | 0.76 | TLR7 (0.41) | TAS1R3TAS1R1P2RX3P2RX2CYP2D6 | |
| SCHEMBL21768595 | 0.74 | P2RX3 (0.40) | TAS1R3TAS1R1TRPC6P2RX3P2RX2 | |
| SCHEMBL20413266 | 0.72 | TRPM8 (0.41) | TAS1R3TAS1R1TLR8TLR7TRPM8 | |
| SCHEMBL21769268 | 0.69 | KCNH2 (0.42) | TRPC6CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL25891581 | 0.69 | MAPT (0.45) | TAS1R3TAS1R1CYP2D6DRD1HTR2A | |
| SCHEMBL22502131 | 0.66 | MCHR1 (0.44) | TLR8 | |
| SCHEMBL20418750 | 0.65 | TLR8 (0.45) | CYP2D6DRD1HTR2AADORA1TLR8 | |
| SCHEMBL6469022 | 0.64 | HCAR3 (0.38) | TAS1R3TAS1R1 | |
| SCHEMBL29637494 | 0.64 | NOS3 (0.44) | EGFRTRPC6P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10780089-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2020-09-22 | — | — | US | disclosed |
| US-20200061059-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780089-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | TAS1R3 4063/4885TAS1R1 4059/4885EGFR 2694/4885 |
| US-20200061059-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | TAS1R3 4063/4885TAS1R1 4059/4885EGFR 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.